Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

Impact · against what's priced in

The positive Phase 1b data for brezosiran is a positive development but represents a new pipeline catalyst rather than a reversal of the core bearish assumptions driving the stock. While it adds value to the long-term pipeline, it does not address the primary market concerns regarding TTR volume normalization and competitive threats from BridgeBio.

ALNY+0.20: Not in the price yet
In context: The positive Phase 1b results for brezosiran in Huntington's disease introduce a new potential value driver that is neither accounted for in the current revenue deceleration assumptions nor listed as a declined pipeline success like Alzheimer's.

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

What matters in this story

How each ticker is affected

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

What matters in this story

How each ticker is affected

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Track these names every morning.

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit

Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

What matters in this story

How each ticker is affected

Next reads from the same story arc

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Alnylam Announces Positive Initial Phase 1b Data for Brezosiran (ALN-HTT02) Demonstrating Deep and Durable Huntingtin Lowering in Huntington's Disease

What matters in this story

How each ticker is affected

Next reads from the same story arc

Stock Market Today, Oct. 22: Moderna Stock Plummets 18% on Melanoma Vaccine Data Leak Reports

Track these names every morning.

Rani Therapeutics Eyes 2027 Obesity Data as Oral Biologics Platform Advances

Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit

Telix Pharmaceuticals: The ITM Deal Could Strengthen The Long-Term Buy Case

Ondine Biomedical says Canadian hospital findings reinforces Steriwave's point of care value